The Muscular Dystrophy Association has funded 40 new research initiatives targeting nearly two dozen progressive neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). New projects are underway in the US and internationally to find effective treatments for these diseases.
The Muscular Dystrophy Association has awarded $13.5 million in grants to support new research on neuromuscular diseases, including muscular dystrophies and ALS. The funding will aid in advancing understanding of disease processes and developing therapeutic strategies for these devastating conditions.
The Muscular Dystrophy Association granted Acceleron Pharma a $1.5 million award to support the clinical studies of ACE-031 in Duchenne Muscular Dystrophy patients. The grant will enable gathering safe dosing and pharmacodynamic activity information vital to future studies.
The Muscular Dystrophy Association has awarded $1.4 million to Repligen to complete preclinical work and initiate human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA). The grant will enable the company to move its lead compound, RG3039, into phase I trials in healthy volunteers and patients with SMA.
The Muscular Dystrophy Association (MDA) has announced $5 million in new grants to support cutting-edge research projects tackling muscle diseases such as muscular dystrophy, ALS, and spinal muscular atrophy. Researchers at top institutions will explore groundbreaking treatments and therapies for these devastating conditions.